Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received
- PMID: 20435259
- DOI: 10.1016/j.jvs.2010.01.074
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received
Erratum in
- J Vasc Surg. 2010 Dec;52(6):1751. Bhattachary, V [corrected to Bhattacharya, V]
Abstract
Background: An intention-to-treat analysis of randomized Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial data showed that initial randomization to a bypass surgery (BSX)-first strategy was associated with improvements in subsequent overall survival (OS) and amputation-free survival (AFS) of about 7 and 6 months, respectively. We describe the nature and timing of first, crossover, and reinterventions and examine AFS and OS by first treatment received. We also compare vein with prosthetic BSX and transluminal with subintimal balloon angioplasty (BAP) and examine outcomes from BSX after failed BAP.
Methods: We randomly assigned 452 patients with SLI due to infrainguinal disease in 27 United Kingdom hospitals to a BSX first (n = 228) or a BAP first (n = 224) revascularization strategy. All patients have been monitored for 3 years and more than half for >5 years. We prospectively collected data on every procedure, major amputation, and death.
Results: Patients randomized to BAP were more likely to have their assigned treatment first (94% vs 85%, P = .01, chi(2)test). BAP had a higher immediate technical failure rate of 20% vs 2.6% (P = .01, chi(2)test). By 12 weeks after randomization 9 BAP (4%) vs 23 BSX (10%) patients had not undergone revascularization; 3 BAP (1.3%) vs 13 BSX (5.8%) had undergone the opposite treatment first; and 35 BAP (15.6%) and 2 (0.9%) BSX had received the assigned treatment and then undergone the opposite treatment. BSX distal anastomoses were divided approximately equally between the above and below knee popliteal and crural arteries; most originated from the common femoral artery. About 25% of the grafts were prosthetic and >90% of vein BSX used ipsilateral great saphenous vein. Most (80%) BAP patients underwent treatment of the SFA alone (38%) or combined with the popliteal artery (42%) and crural arteries (20%). Outcome of vein BSX was better for AFS (P = 0.003) but not OS (P = 0.38, log-rank tests) than prosthetic BSX. There were no differences in outcome between approximately equal numbers of transluminal and subintimal BAP. AFS (P = 0.006) but not OS (P = 0.06, log rank test) survival was significantly worse after BSX after failed BAP than after BSX as a first revascularization attempt.
Conclusions: BAP was associated with a significantly higher early failure rate than BSX. Most BAP patients ultimately required surgery. BSX outcomes after failed BAP are significantly worse than for BSX performed as a first revascularization attempt. BSX with vein offers the best long term AFS and OS and, overall, BAP appears superior to prosthetic BSX.
Crown Copyright (c) 2010. Published by Mosby, Inc. All rights reserved.
Similar articles
-
A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia.J Vasc Surg. 2018 Aug;68(2):624-633. doi: 10.1016/j.jvs.2018.01.066. Epub 2018 May 24. J Vasc Surg. 2018. PMID: 29804736 Review.
-
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia.J Vasc Surg. 2010 May;51(5 Suppl):69S-75S. doi: 10.1016/j.jvs.2010.02.001. J Vasc Surg. 2010. PMID: 20435263 Review.
-
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival prediction model to facilitate clinical decision making.J Vasc Surg. 2010 May;51(5 Suppl):52S-68S. doi: 10.1016/j.jvs.2010.01.077. J Vasc Surg. 2010. PMID: 20435262 Clinical Trial.
-
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis.J Vasc Surg. 2010 May;51(5 Suppl):43S-51S. doi: 10.1016/j.jvs.2010.01.076. J Vasc Surg. 2010. PMID: 20435261 Clinical Trial.
-
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy.J Vasc Surg. 2010 May;51(5 Suppl):5S-17S. doi: 10.1016/j.jvs.2010.01.073. J Vasc Surg. 2010. PMID: 20435258 Clinical Trial.
Cited by
-
Endovascular Transvenous versus Open Femoropopliteal Bypass.Medicina (Kaunas). 2024 May 8;60(5):777. doi: 10.3390/medicina60050777. Medicina (Kaunas). 2024. PMID: 38792960 Free PMC article.
-
Carotid Artery Bypass Surgery of In-Body Tissue Architecture-Induced Small-Diameter Biotube in a Goat Model: A Pilot Study.Bioengineering (Basel). 2024 Feb 21;11(3):203. doi: 10.3390/bioengineering11030203. Bioengineering (Basel). 2024. PMID: 38534477 Free PMC article.
-
Valvulotomy of the great saphenous vein in ex situ non-reversed and in situ setting: a multicenter post-market study to assess the safety and efficacy of the AndraValvulotome™".Langenbecks Arch Surg. 2023 Nov 30;408(1):449. doi: 10.1007/s00423-023-03189-5. Langenbecks Arch Surg. 2023. PMID: 38030864 Free PMC article.
-
Molecular cues for immune cells from small leucine-rich repeat proteoglycans in their extracellular matrix-associated and free forms.Matrix Biol. 2023 Nov;123:48-58. doi: 10.1016/j.matbio.2023.10.001. Epub 2023 Oct 2. Matrix Biol. 2023. PMID: 37793508 Review.
-
Peripheral arterial disease treatment planning using noninvasive and invasive imaging methods.J Vasc Surg Cases Innov Tech. 2023 Aug 19;9(4):101263. doi: 10.1016/j.jvscit.2023.101263. eCollection 2023 Dec. J Vasc Surg Cases Innov Tech. 2023. PMID: 37767348 Free PMC article.
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources